Xu Zheng

Xu Zheng

Auto-generated profile, based on publicly available information

Xu Zheng

Second Affiliated Hospital of Zhejiang Chinese Medical University Hangzhou China

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Phytomedicine
Verified
Journal Article
Closed access
XZXiang Zhou
Xiang Zhou
WWWei-Ming Wang
Wei-Ming Wang
ZLZhaofeng Li
Zhaofeng Li
LCLin Chen
Lin Chen
CWChunmei Wen
Chunmei Wen
JDJie Deng
Jie Deng

24 June 2025 in Natural Product Communications
Verified
Journal Article
Open access
ZXZheng Xu
Zheng Xu
SWShuoshi Wang
Shuoshi Wang
KSKaishun Shi
Kaishun Shi
JHJie Huang
Jie Huang
YYYuebing Yue
Yuebing Yue
XZXiaoping Zhang
Xiaoping Zhang
Panax notoginseng (Burk.) F. H. Chen, an esteemed herbal medicine in traditional Chinese medicine (TCM), is notable for its bioactive compounds, particularly Panax notoginseng saponins (PNS), which exhibit a diverse range of pharmacological effects, including anti-inflammatory, antioxidant, anti-apoptotic, and anti-tumor properties, thereby providing significant therapeutic benefits in the context of cardiovascular, nervous system, and immune disorders. The aim of this study was to elucidate the contemporary research trends associated with PNS and to provide a roadmap for future investigative directions. A comprehensive review of the literature on PNS published from 2000 to 2024 was conducted utilizing the Web of Science Core Collection (WoSCC) database, supplemented by analytical tools such as VOSviewer and CiteSpace, which facilitated the identification of several emergent research hotspots, namely “endoplasmic reticulum stress,” “gut microbiota,” “pyroptosis,” “ferroptosis,” and “network pharmacology.” The findings of this groundwork not only highlight the dynamic interest surrounding PNS within the scientific community but also delineate specific thematic avenues that warrant further exploration, thereby fostering future research initiatives aimed at fully elucidating the multifaceted therapeutic potential of PNS in various pathological contexts.

16 November 2004 in Blood
Verified
Journal Article
Open access
KOKen-Ichiro Otsuyama
Ken-Ichiro Otsuyama
ZMZi Ma
Zi Ma
SLShangqin Liu
Shangqin Liu
FLFu-Jun Li
Fu-Jun Li
SASaeid Abroun
Saeid Abroun
MKMichio M. Kawano
Michio M. Kawano
Growth expansion of monoclonal plasma cells (myeloma cells) in the bone marrow (BM) is triggered by increase in serum interleukin-6 (IL-6). Indeed, high levels of IL-6 have been found in the serum of patients with progressive multiple myeloma (MM), and a reduction of the tumor cell mass has been reported by inhibition of myeloma cell proliferation with anti-IL-6 antibodies. On the other hand, IL-6 is considered to increase physiologically in its serum level along with age, and the age-related increase in serum IL-6 could be related to the age-dependent diseases such as rheumatoid arthritis, atherosclerosis, Alzheimer’s disease and B cell malignancies including myelomas. Recent reports also show that the age-associated decline in the serum level of an adrenal sex hormone, dehydroepiandrosterone sulfate (DHEA-S), is closely related to the increase in serum IL-6. Here, we show that DHEA-S is decreased significantly more than that by physiological decline with age in overt myeloma, but not in other lymphoid malignancies such as malignant lymphoma or macroglobulinemia. DHEA-S as well as DHEA suppressed IL-6 production from a BM stromal cell line, KM-102, and bone marrow mononuclear cells from patients with MM. Furthermore, DHEA inhibited in vitro growth of the U-266 cell line and primary myeloma cells from the patients, and also in vivo growth of U-266 cells intraperitoneally implanted in SCID-hIL6 transgenic mice. DHEA upregulated the expression of peroxisome proliferator activated receptor (PPAR)β and IκBα gene in myeloma cells and BM stromal cells, which could explain the suppressive effect of DHEA on IL-6 production through the downregulation of NF-κB activity. PPAR agonists such as troglitazone, carbacyclin and WY14643, also inhibited the growth of myeloma cell lines and primary myeloma cells. Therefore, these findings suggest that DHEA has a capability of inhibiting the growth of myeloma cells and IL-6 production of bone marrow mononuclear cells through activation of PPAR and/or suppression of NFκB activity, and inversely a decreased level of DHEA and DHEA-S could upregulate IL-6 activity, which could be responsible for progression of myeloma cells.

16 November 2004 in Blood
Verified
Journal Article
Open access
XZXu Zheng
Xu Zheng
HIHideaki Ishikawa
Hideaki Ishikawa
NTNaohiro Tsuyama
Naohiro Tsuyama
SASaeid Abroun
Saeid Abroun
SLShangqin Liu
Shangqin Liu
MKMichio M. Kawano
Michio M. Kawano
CD19 is a B cell-specific membrane protein belonging to immunoglobulin superfamily, and acts as a positive or negative regulator in B cell signaling. Although plasma cells still express CD19, CD19 expression is lost in malignant plasma cells with the progression of multiple myeloma (MM) including monoclonal gammopathy of undermined significance (MGUS). To understand the pathological significance of loss of CD19 in human myelomas, we examined the biological effect of CD19 expression on myeloma cells by generating CD19 transfectants of a myeloma cell line, U266. CD19 transfectants showed slower growth rate in vitro than controls, such as mock and ΔCD19 transected with a truncated form of CD19. The growth-inhibitory effect was CD19-specific and presumably due to the intracellular signaling events via CD19 because this effect was not observed in ΔCD19. Furthermore, serum withdrawal rapidly induced the apoptosis of the CD19-transfectants that was rescued by insulin-like growth factor (IGF-I) as compared with CD19− controls. These may suggest that the CD19 transfectants are likely to be dependent on the growth factors, such as IGF-I, to survive and proliferate, and thus, susceptible to the serum deprivation-induced apoptosis. IGF-I activates extracellular signal-regulated kinase (ERK) 1/2 and phosphatidylinositol-3-kinase (PI-3K) that are important for proliferation of myeloma cells. Western bolt analysis showed that IGF-1-induced activation of ERK1/2 was reduced in the CD19 transfectants, although the similar levels of IGF-I receptors were expressed in the CD19 transfectants and CD19− controls. In contract, CD19 failed to inhibit the IGF-I-mediated PI-3K/AKT activation, whereas a downstream target in the PI-3K pathway, p70S6 kinase activation was decreased in the CD19 transfectants. However, the p70S6 kinase activity could be influenced by both ERK1/2 and PI-3K pathways after IGF-1 stimulation, and the MAPK pathway seems to be a major regulator for myeloma cell growth. Our results, therefore, suggest that the recovering expression of CD19 molecules and genes in human myeloma cells may be an important consideration in therapeutic approaches in human MM.

21 January 2026 in Phytotherapy Research
Verified
Journal Article
Closed access
ZXZheng Xu
Zheng Xu
YLYing Lu
Ying Lu
SSShuying Si
Shuying Si
YYYuebing Yue
Yuebing Yue
XWXinchang Wang
Xinchang Wang
JHJie Huang
Jie Huang

16 November 2005 in Blood
Verified
Journal Article
Open access
XZXu Zheng
Xu Zheng
MMMaged S. Mahmoud
Maged S. Mahmoud
SASaeid Abroun
Saeid Abroun
HAHideki Asaoku
Hideki Asaoku
MKMichio M. Kawano
Michio M. Kawano
CD19 expression is specifically lost on human myeloma cells by the loss of Pax-5 gene expression, while normal plasma cells do express CD19. In order to examine the biological meaning of the loss of CD19 expression in human myeloma cells, we have generated CD19 transfectants of human myeloma cell lines (U266 and KMS-5 cells) and of a human non-myeloma erythroleukemia cell line (K562) and compared their proliferation and survival with those of their corresponding parent or only vector-transfected cells in the serum-containing or serum-free medium (supplemented with BSA and transferrin) in vitro. Exogenous introduction of CD19 expression markedly suppressed the proliferation of these cells in the serum-containing medium, but there existed less suppressive effect of CD19 introduction in serum-free culture. Among the serum components, we focused on the IgG and examined the effect of addition of high concentration of IgG or addition of anti-CD32 (FcγRII) antibody in this serum-free medium. Addition of high concentration of IgG induced the marked suppression of CD19 transfectants more than that of parent or mock transfectants, and furthermore, stimulation with anti-CD32 antibody also showed the suppression of CD19 transfectants more than that of the mock cells. We also confirmed that primary myeloma cells as well as myeloma cell lines predominantly expressed FcγRII(CD32), but not FcγRI(CD64) or FcγRIII(CD16), and were found to express FcγRIIB gene by RT-PCR. Furthermore, the treatment with anti-CD32 antibody induced the tyrosine phosphorylation of CD32b in the CD19+ cells more than that in CD19- mock cells, and also the phosphorylation of SHIP, but not SHP-1 or SHP-2 was enhanced in CD19+ cells. Therefore, these data suggest that myeloma cells as well as plasma cells or B cells express FcγRII(CD32), and CD19- myeloma cells are less sensitive to the FcγRII-mediated growth suppression than CD19+ normal plasma cells or B cells.